ArticleCancer genomics & proteomics
Beta-site Amyloid Precursor Protein Cleaving Enzyme 1 Overexpression Abrogates ST6GAL1 Mediated Rectal Cancer Chemoradiation Resistance.
Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND/
aimSialyltransferase ST6GAL1 is known to be upregulated in various cancer types, including rectal cancer, and is linked to poor prognosis. This enzyme catalyzes the addition of sialic acids to various proteins, altering their activity and function. Our lab has previously shown that ST6GAL1 causes resistance to chemoradiation therapy (CRT) in rectal cancer, via sialylation of tumor necrosis factor receptor 1 (TNFR1). This leads to decreased TNFR1 mediated cell death/apoptosis. We aimed to elucidate whether beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), which cleaves ST6GAL1, has a role in treatment response to CRT and whether its overexpression (OE) could improve response to CRT. MATERIALS AND
methodsWe first assessed BACE1 and ST6GAL1 in pre-treatment biopsies from rectal cancer patients. We then evaluated the effects of BACE1 modulation in CRC cell lines. The high BACE1-expressing CRC cell line SW1463 was utilized for inhibition studies, and SW620 CRC cells lines were additionally lentivirally transfected for OE of BACE1 (validated by flow cytometry, qPCR, Western Blotting, and activity assay). BACE1 OE cells were also utilized for response to CRT.
resultsAnalysis of patient biopsies showed that BACE1 mRNA was significantly increased in patients with a complete response to CRT. SW1463 colorectal cancer cells treated with a BACE1 inhibitor had increased cell-surface sialylation and increased survival after CRT compared to vehicle-treated cells. BACE1 overexpressing SW620 CRC clones exhibited protein expression and activity of BACE1, with reduced ST6GAL1 protein. BACE1 OE colorectal cancer cells also had significantly increased apoptosis and decreased survival after CRT. BACE1 OE clones had decreased sialylation of the apoptosis receptor, TNFR1.
conclusionCollectively, we found that overexpressing BACE1 altered ST6GAL1-mediated CRT resistance in CRC cells. BACE1 enzymatic cleavage of ST6GAL1 may be a potential target for improving therapeutic response to CRT in rectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.